PepGen Inc. 宣布，在独立数据安全监查委员会（DSMB）完成审查后，其候选药物 PGN-EDODM1 将迈入 2 期 FREEDOM2-DM1 研究的最高剂量队列。这一进展标志着该药物在治疗 1 型强直性肌营养不良症（DM1）的临床开发中取得了关键性突破。公司决定让 PGN-EDODM1 进入更高剂量组别，旨在进一步评估其安全性与有效性，为患者带来潜在的新疗法。
PepGen Inc. 宣布，在独立数据安全监查委员会（DSMB）完成审查后，其候选药物 PGN-EDODM1 将迈入 2 期 FREEDOM2-DM1 研究的最高剂量队列。这一进展标志着该药物在治疗 1 型强直性肌营养不良症（DM1）的临床开发中取得了关键性突破。公司决定让 PGN-EDODM1 进入更高剂量组别，旨在进一步评估其安全性与有效性，为患者带来潜在的新疗法。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.